To Kentaro, Miyake Noriko, Nagasaki Yoji, Shimono Nobuyuki
Department of Clinical Immunology and Rheumatology/Infectious Diseases, Kyushu University Hospital.
Jpn J Antibiot. 2011 Dec;64(6):389-94.
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.
耐甲氧西林金黄色葡萄球菌（MRSA）引起的感染性心内膜炎是一种严重疾病，有时会导致预后不良。我们应该有多种治疗选择。阿贝卡星是氨基糖苷类抗生素之一，对MRSA的活性更强，且比庆大霉素的肾毒性更小。在此，我们报告了一例通过监测万古霉素和阿贝卡星的治疗水平成功治疗的严重MRSA心内膜炎病例，且未出现任何不良反应。
